Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 14/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2462209 | 1.00 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL2460843 | 1.00 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL203905 | 1.00 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL29418355 | 1.00 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL2329779 | 0.95 | CCR2 (0.67) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL4704983 | 0.95 | CCR2 (0.67) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL2462379 | 0.95 | CCR2 (0.67) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL7327118 | 0.93 | CCR2 (0.57) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL7327122 | 0.93 | CCR2 (0.57) | CCR2GAACCR1CCR5CXCR4 | |
| Acetic Acid SCHEMBL8778037 | 0.92 | CCR2 (0.62) | CCR2GAACCR1CCR5CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4644380-A1 | PYRIDAZINE NLRP3 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| CN-115916207-A | Five-membered and six-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors | 轶诺(浙江)药业有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11530183-B2 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-12-20 | — | — | US | disclosed |
| CN-106588890-B | Antiviral compounds | 吉利德制药有限责任公司 | 2020-11-27 | — | — | CN | disclosed |
| EP-3626716-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3002281-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011117160-A1 | PYRROLOPYRAZINE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230414-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
| CN-101270076-B | Method for preparing natural product (3S,9S)-Ciliatamides C | UNIV FUDAN | 2011-04-27 | — | — | CN | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-7531657-B2 | Method for preparing sulphostin and analogue thereof or preparation intermediate thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-05-12 | — | — | US | disclosed |
| CN-101270076-A | Method for preparing natural product (3S,9S)-Ciliatamides C | UNIV FUDAN (CN) | 2008-09-24 | — | — | CN | disclosed |
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1457494-A1 | PROCESSES FOR PREPARATION OF SULPHOSTIN AND ITS ANALOGUES OR INTERMEDIATES THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | SOST, PTMS, FGF23 | CCR2 1659/4885GAA 2919/4885CCR1 930/4885 |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CCR2 1607/4885GAA 151/4885CCR1 795/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CCR2 1607/4885GAA 151/4885CCR1 795/4885 |
| US-11530183-B2 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | FPR1, FPR2, FPR3 | CCR2 13/4885GAA 4579/4885CCR1 81/4885 |
| US-20110230414-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | CCR2 1035/4885GAA 3087/4885CCR1 2908/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CCR2 1607/4885GAA 151/4885CCR1 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.